Syngene International (SYNGENE) Q3 24/25 earnings summary

Executive summary

• Q3 FY25 saw revenue from operations rise to INR 9,437 million, up 11% year-over-year, with strong contributions from Research Services and CDMO, especially biologics, and pilot projects converting to long-term contracts.

• Net profit for Q3 FY25 increased 18% year-over-year after exceptional items, reaching INR 1,311 million.

• The acquisition and renovation of a biologics manufacturing facility in Bangalore (Unit 3) added significant capacity and capabilities, supporting future growth.

• Development and Manufacturing Services maintained steady performance, driven by repeat biologics orders and new integrated collaborations.

• Insurance claim income and accounting changes, including tax provision reversals and asset depreciation adjustments, impacted reported results.

Financial highlights

• Q3 FY25 revenue from operations was INR 9,437 million, up 11% year-over-year; EBITDA margin improved to 31.4% from 29.5% a year ago.

• Q3 FY25 PAT before exceptional items rose 14% year-over-year to INR 1,311 million; after exceptional items, PAT increased 18% year-over-year.

• For the nine months, revenue from operations reached INR 26,244 million, up 2% year-over-year; EBITDA margin at 28.1% vs 29.2% in 9M FY24.

• Net cash position as of December 31, 2024, was INR 8,383 million.

• Q3 FY25 consolidated profit before tax: INR 1,808 million; consolidated EPS (basic): INR 3.27.

Outlook and guidance

• Growth momentum is expected to continue in Q4, with full-year revenue growth in single digits and flat EBITDA.

• Conversion of pilot projects to full contracts in Discovery Services and the new biologics facility are expected to drive future growth.

• CapEx program remains on track for $60 million for the year, with continued investment in capacity and capabilities.